FDA Grants Priority Review to Frontline Pembrolizumab Combo for NSCLC

11 gennaio 2017 – The FDA has granted a priority review to a supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) in combination with pemetrexed plus carboplatin as a treatment for patients with metastatic or advanced non-squamous non–small cell lung cancer (NSCLC), regardless of PD-L1 expression and without EGFR or ALK mutations. The sBLA was based on part 2 of cohort G in the KEYNOTE-021 trial, in which the … (leggi tutto)